Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-myeloablative transplants for malignant disease.

R F Storb1, R Champlin, S R Riddell

  • 1Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.

Hematology. American Society of Hematology. Education Program
|November 28, 2001
PubMed
Summary

Future hematopoietic stem cell transplants focus on the graft-versus-tumor effect, reducing toxicity and expanding eligibility. Non-myeloablative approaches utilize donor immune cells to target malignant hematological diseases, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

Gene therapy·2014
Same author

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.

Tissue antigens·2013
Same author

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma.

Bone marrow transplantation·2009
Same author

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.

Bone marrow transplantation·2007
Same author

Optimization of allogeneic transplant conditioning: not the time for dogma.

Leukemia·2006
Same author

T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma.

Cytotherapy·2002

Area of Science:

  • Hematology and Oncology
  • Immunology
  • Transplantation Medicine

Background:

  • Conventional high-dose chemoradiation therapy for malignant hematological diseases carries significant morbidity and mortality.
  • A paradigm shift is occurring in hematopoietic stem cell allotransplantation, moving towards leveraging the donor's immune system.
  • Non-myeloablative transplant approaches offer a less toxic alternative, expanding treatment options for elderly or medically infirm patients.

Purpose of the Study:

  • To discuss the evolution of hematopoietic stem cell allotransplantation strategies for malignant hematological diseases.
  • To highlight the potential of non-myeloablative approaches and the graft-versus-tumor effect.
  • To explore future possibilities of eliciting specific graft-versus-tumor responses through minor histocompatibility antigens.

Related Experiment Videos

Main Methods:

  • Experimental studies in dogs using non-cytotoxic immunosuppressive agents to establish stable allografts.
  • Clinical translation of reduced-intensity conditioning regimens, including low-dose total body irradiation (TBI) and fludarabine.
  • Studies on isolating T cells reactive with minor histocompatibility antigens involved in graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL).

Main Results:

  • Non-myeloablative conditioning, including a single dose of 2 Gy TBI with or without fludarabine, has been successfully used in over 300 patients.
  • Therapeutic strategies utilizing non-myeloablative regimens have shown remissions in various leukemias, lymphomas, and myelomas.
  • Identification of minor histocompatibility antigens and development of T-cell clones specific for these antigens show promise in preventing engraftment of leukemia cells and treating relapsed disease.

Conclusions:

  • Non-myeloablative hematopoietic stem cell allotransplantation significantly reduces toxicity and mortality, enabling treatment for a broader patient population.
  • Harnessing the graft-versus-tumor effect, particularly through minor histocompatibility antigens, offers a promising avenue for targeted cancer therapy.
  • Ongoing clinical trials and research into minor antigen-specific T-cell therapies are advancing the field of allogeneic stem cell transplantation.